Compugen to Announce Q2 2024 Results on August 6, 2024

HOLON, Israel, July 23, 2024 -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and pioneer in computational target discovery, announced that it will release its financial results for the second quarter of 2024 on Tuesday, August 6, 2024, before the U.S. financial markets open. The company’s management will lead a conference call and webcast to discuss the results and provide a corporate update at 8:30 AM ET.

Interested parties in the U.S. can join the live conference call by dialing 1-866-744-5399, while international participants can dial +972-3-918-0644. The call will also be accessible via live webcast on Compugen's website, with a replay available shortly after the webcast concludes.

About Compugen 

Compugen operates as a clinical-stage company focused on therapeutic discovery and development, utilizing its predictive computational discovery capabilities to identify novel drug targets and biological pathways for cancer immunotherapy development. The company has developed two proprietary product candidates: COM701 and COM902. 

COM701 is a potential first-in-class anti-PVRIG antibody, and COM902 is a potential best-in-class antibody targeting TIGIT, both intended for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody derived from Compugen's COM902, is currently in Phase 3 development through a license agreement with AstraZeneca for developing bispecific and multispecific antibodies.

Additionally, Compugen's early-stage immuno-oncology pipeline includes programs targeting various mechanisms of immune resistance. The most advanced of these programs, COM503, is in IND enabling studies and licensed to Gilead. COM503 is a potential first-in-class, high-affinity antibody that blocks the interaction between IL-18 binding protein and IL-18, thus allowing natural IL-18 to inhibit cancer growth within the tumor microenvironment.

Compugen’s headquarters are located in Israel, with additional offices in San Francisco, CA. The company's shares are traded on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!